Results 21 to 30 of about 13,805 (198)

Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review

Pharmaceutics, 2023
The actinium-225 (225Ac) radioisotope exhibits highly attractive nuclear properties for application in radionuclide therapy. However, the 225Ac radionuclide presents multiple daughter nuclides in its decay chain, which can escape the targeted site ...
Sipho Mdanda, Lindokuhle M. Ngema, Amanda Mdlophane, Mike M. Sathekge, Jan Rijn Zeevaart   +4 more
doaj   +1 more source

What is the role of the bystander response in radionuclide therapies?

Frontiers in Oncology, 2013
Radionuclide therapy for cancer is undergoing a renaissance, with a wide range of radionuclide and clinical delivery systems currently under investigation.
Darren eBrady, Joe M O'Sullivan, Kevin M Prise   +2 more
doaj   +1 more source

Targeted Radionuclide Therapy of Human Tumors [PDF]

International Journal of Molecular Sciences, 2015
Targeted radionuclide therapy is one of the most intensively developing directions of nuclear medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy causes less collateral damage to normal tissues and allows targeted drug delivery to a clinically diagnosed neoplastic malformations, as well as metastasized cells and ...
Sergey Gudkov, Natalya Shilyagina, Vladimir Vodeneev, Andrei Zvyagin   +3 more
openaire   +2 more sources

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy

Frontiers in Medicine, 2021
Samarium-153 (153Sm) is a highly interesting radionuclide within the field of targeted radionuclide therapy because of its favorable decay characteristics.
Michiel Van de Voorde, Charlotte Duchemin, Charlotte Duchemin, Reinhard Heinke, Reinhard Heinke, Laura Lambert, Eric Chevallay, Thomas Schneider, Miranda Van Stenis, Thomas Elias Cocolios, Thomas Cardinaels, Thomas Cardinaels, Bernard Ponsard, Maarten Ooms, Thierry Stora, Andrew R. Burgoyne   +15 more
doaj   +1 more source

Targeted radionuclide therapies for pancreatic cancer [PDF]

Cancer Gene Therapy, 2015
Pancreatic malignancies, the fourth leading cause of cancer deaths, have an aggressive behavior with poor prognosis, resulting in a 5-year survival rate of only 4%. It is typically a silent malignancy until patients develop metastatic disease. Targeted radionuclide therapies of cancer such as radiolabeled peptides, which bind to the receptors ...
M, Shah, R, Da Silva, C, Gravekamp, S K, Libutti, T, Abraham, E, Dadachova   +5 more
openaire   +2 more sources

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review

Frontiers in Chemistry, 2023
Copper has several clinically relevant radioisotopes and versatile coordination chemistry, allowing attachment of its radionuclides to biological molecules.
Mazhar Hussain, Mazhar Hussain, Syed M. Qaim, Ingo Spahn, M. Naveed Aslam, Bernd Neumaier   +5 more
doaj   +1 more source

Peptide-targeted radionuclide therapy for melanoma [PDF]

Critical Reviews in Oncology/Hematology, 2008
Melanocortin-1 receptor (MC1-R) and melanin are two attractive melanoma-specific targets for peptide-targeted radionuclide therapy for melanoma. Radiolabeled peptides targeting MC1-R/melanin can selectively and specifically target cytotoxic radiation generated from therapeutic radionuclides to melanoma cells for cell killing, while sparing the normal ...
Yubin, Miao, Thomas P, Quinn
openaire   +2 more sources

First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer

Journal for ImmunoTherapy of Cancer, 2022
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is a validated treatment option for patients with advanced prostate cancer. Although PSMA expression is not limited to prostate tissue, little is known about its relevance to other ...
John Prior, Solange Peters, Krisztian Homicsko, Sarah Boughdad, Niklaus Schaefer, Antonia Digklia, Clarisse Dromain, Mounir Trimech, Ana Dolcan   +8 more
doaj   +1 more source

Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide

Pharmaceutics, 2022
Although immune checkpoint inhibitors (ICI) have revolutionized cancer management, patient response can be heterogeneous, and the development of ICI resistance is increasingly reported.
Carolina de Aguiar Ferreira, Pedram Heidari, Bahar Ataeinia, Nicoleta Sinevici, Alyssa Granito, Hritik Mahajan Kumar, Eric Wehrenberg-Klee, Umar Mahmood   +7 more
doaj   +1 more source

Continuing Nuclear Data Research for Production of Accelerator-Based Novel Radionuclides for Medical Use: A Mini-Review

Frontiers in Physics, 2021
Nuclear data are important for production and medical application of a radionuclide. This brief review concentrates on nuclear reaction cross-section data.
Syed M. Qaim, Mazhar Hussain, Ingo Spahn, Bernd Neumaier   +3 more
doaj   +1 more source